Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer

ALK gene rearrangement was observed in 3%–5% of non-small cell lung cancer patients, and multiple ALK-tyrosine kinase inhibitors (TKIs) have been sequentially used. Multiple ALK-TKI resistance mutations have been identified from the patients, and several compound mutations, such as I1171N + F1174I o...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Nat Commun
Autores principales: Mizuta, Hayato, Okada, Koutaroh, Araki, Mitsugu, Adachi, Jun, Takemoto, Ai, Kutkowska, Justyna, Maruyama, Kohei, Yanagitani, Noriko, Oh-hara, Tomoko, Watanabe, Kana, Tamai, Keiichi, Friboulet, Luc, Katayama, Kazuhiro, Ma, Biao, Sasakura, Yoko, Sagae, Yukari, Kukimoto-Niino, Mutsuko, Shirouzu, Mikako, Takagi, Satoshi, Simizu, Siro, Nishio, Makoto, Okuno, Yasushi, Fujita, Naoya, Katayama, Ryohei
Formato: Artigo
Lenguaje:Inglês
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7904790/
https://ncbi.nlm.nih.gov/pubmed/33627640
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-021-21396-w
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares